GREY:DGCRF - Post by User
Post by
Dibah42on Jan 16, 2014 5:26pm
284 Views
Post# 22101165
Q4: Little to report
Q4: Little to reportRoyalties for PCA3 grew by $83k or 14% in Q4 inspite of HOLX's lackadaisical marketing approach. Total for the year $671k. Cash on hand $4,190,296 or about $0 .097/ share.
In intense communication with HOLX to buy back the rights but no results to show thus far. In some ways, IMO, the serious problems HOLX is having may be a plus for CUR in that they might be disposed to make a deal. Better than an impairment charge.
Not much new to report on GCC.
CUR (i.e. Fradet?) got an NRC grant for $2-300k to validate a new PC marker.
RB seems to be leaning toward a partnership with Arun Chinayan of U. Mich and his TMPRS 2/ERG markers.
They should be targeting big pharmas which have the $$$ and are hungry for pipeline.
Ho hum